Abstract
Background: The evolutionarily conserved Hedgehog (Hh) signaling cascade is one of the key mediators of embryonic development of many metazoans. This pathway has been extensively targeted by small molecule inhibitors as its misregulation leads to various malignancies and developmental disorders. Thus, blocking this pathway can be a novel therapeutic avenue for the treatment of Hedgehog-dependent cancers. This review covers the mechanism of hedgehog signaling in vertebrate cells, provides an overview of reported small molecule Hh pathway inhibitors, with the synthetic routes and SAR studies of some of them discussed briefly.
Methods: A comprehensive survey of literature related to synthetic and naturally occurring Hh signaling antagonists reported till date is presented. Results: Given the selectivity of small molecules targeting, this pathway for cancer treatment compared to kinase, tubulin or HDAC inhibitors, several such antagonists have been discovered, of which some are in preclinical development and clinical studies. Most of the reported small molecules primarily antagonize the Smoothened receptor although agents targeting Gli1 transcription factor and Shh ligand have also been discovered. Till date, nine Smo antagonists have been evaluated in clinical trials.GDC- 0449/Vismodegib and NVP-LDE225/Erismodegib, were granted approval by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of basal cell carcinoma. Conclusion: The challenge is to identify agents that target the pathway downstream of Smo and develop strategies to overcome acquired drug resistance to the current Smo inhibitors with deeper understanding of the resistance mechanisms.Keywords: Hedgehog pathway, small molecule, smoothened, GLI, inhibitors, anticancer.
Current Medicinal Chemistry
Title:Discovery of Hedgehog Antagonists for Cancer Therapy
Volume: 24 Issue: 19
Author(s): Harleen Khatra, Chandra Bose and Surajit Sinha*
Affiliation:
- Department of Organic Chemistry, Indian Association for the Cultivation of Science, Jadavpur, Kolkata 700 032,India
Keywords: Hedgehog pathway, small molecule, smoothened, GLI, inhibitors, anticancer.
Abstract: Background: The evolutionarily conserved Hedgehog (Hh) signaling cascade is one of the key mediators of embryonic development of many metazoans. This pathway has been extensively targeted by small molecule inhibitors as its misregulation leads to various malignancies and developmental disorders. Thus, blocking this pathway can be a novel therapeutic avenue for the treatment of Hedgehog-dependent cancers. This review covers the mechanism of hedgehog signaling in vertebrate cells, provides an overview of reported small molecule Hh pathway inhibitors, with the synthetic routes and SAR studies of some of them discussed briefly.
Methods: A comprehensive survey of literature related to synthetic and naturally occurring Hh signaling antagonists reported till date is presented. Results: Given the selectivity of small molecules targeting, this pathway for cancer treatment compared to kinase, tubulin or HDAC inhibitors, several such antagonists have been discovered, of which some are in preclinical development and clinical studies. Most of the reported small molecules primarily antagonize the Smoothened receptor although agents targeting Gli1 transcription factor and Shh ligand have also been discovered. Till date, nine Smo antagonists have been evaluated in clinical trials.GDC- 0449/Vismodegib and NVP-LDE225/Erismodegib, were granted approval by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of basal cell carcinoma. Conclusion: The challenge is to identify agents that target the pathway downstream of Smo and develop strategies to overcome acquired drug resistance to the current Smo inhibitors with deeper understanding of the resistance mechanisms.Export Options
About this article
Cite this article as:
Khatra Harleen , Bose Chandra and Sinha Surajit*, Discovery of Hedgehog Antagonists for Cancer Therapy, Current Medicinal Chemistry 2017; 24 (19) . https://dx.doi.org/10.2174/0929867324666170316115500
DOI https://dx.doi.org/10.2174/0929867324666170316115500 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemical Constituents and Biological Activity of Chinese Medicinal Herb ‘Xihuangcao’
Combinatorial Chemistry & High Throughput Screening Moderate Hypothermia in the Management of Severe Traumatic Brain Injury: A Good Idea Proved Ineffective?
Current Pharmaceutical Design Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Recent Developments in the Pharmacological Properties of 4'-Geranyloxyferulic Acid, a Colon Cancer Chemopreventive Agent of Natural Origin
Current Drug Targets Structure-Function Relationship of Thiazolides, a Novel Class of Anti-Parasitic Drugs, Investigated in Intracellular and Extracellular Protozoan Parasites and Larval-Stage Cestodes
Anti-Infective Agents in Medicinal Chemistry Novel Ligands: Fine Tuning the Transcriptional Activity of the Glucocorticoid Receptor
Current Pharmaceutical Design Sunitinib (SUTENT, SU11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma
Current Cancer Drug Targets Towards Drug Discovery for Brain Tumours: Interaction of Kinins and Tumours at the Blood Brain Barrier Interface
Recent Patents on CNS Drug Discovery (Discontinued) Insight into p95HER2 in Breast Cancer: Molecular Mechanisms and Targeted Therapies
Recent Patents on DNA & Gene Sequences Modulation of Angiogenesis by Inflammatory Markers and the Role of Matrix Metalloproteinases in an Endothelial Cell/Fibroblast Co-culture System
Current Angiogenesis (Discontinued) Regulation of MicroRNAs by Phytochemicals: A Promising Strategy for Cancer Chemoprevention
Current Cancer Drug Targets Class III β -Tubulin (TUBB3): More than a Biomarker in Solid Tumors?
Current Molecular Medicine Revisiting Non-Cancer Drugs for Cancer Therapy
Current Topics in Medicinal Chemistry The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Selective Androgen Receptor Modulators Antagonize Apolipoprotein E4-Induced Cognitive Impairments
Letters in Drug Design & Discovery Endogenous Regulators of Adult CNS Neurogenesis
Current Pharmaceutical Design MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers Virtual Screening of NCI Diversity Set II Lead to New Cyclin-Dependent Kinases 5 Inhibitors Using AutoDock
Letters in Drug Design & Discovery Epigenetic Basis of Individual Variability to Major Psychosis
Current Pharmacogenomics and Personalized Medicine